专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006056144A3 OSMOTIC DEVICE CONTAINING LICOFELONE 审中-公开
标题翻译：含有Lofofone的渗透装置
公开(公告)号：WO2006056144A3
公开(公告)日：2006-08-17
申请号：PCT/CR2004000007
申请日：2004-12-10
申请人： OSMOTICA CORP , VERGEZ JUAN A , FAOUR JOAQUINA , RICCI MARCELO A , BEFUMO MARCELO E
发明人： VERGEZ JUAN A , FAOUR JOAQUINA , RICCI MARCELO A , BEFUMO MARCELO E
IPC分类号： A61K9/22 , A61K9/00 , A61K9/28 , A61K31/40 , A61K31/407 , A61K31/415
CPC分类号： A61K9/0004 , A61K9/2886 , A61K31/407 , A61K31/415
摘要： The invention relates to an osmotic device containing controlled-release licofelone and, optionally, rapid-release licofelone in an external coating. The inventive osmotic device delivers a controlled release of licofelone in order to maintain therapeutically-effective plasmatic levels of licofelone when it is administered once daily. The device can be used for the treatment of osteoarthritis, rheumatoid arthritis and associated inflammatory disorders. According to the invention, said devices can be used to deliver licofelone using specific release profiles combined with specific formulations.
摘要翻译：本发明涉及渗透装置，其含有控释Licofelone和任选地在外部涂层中的速释Licofelone。本发明的渗透装置递送Licofelone的受控释放，以在每天一次施用时保持Licofelone的治疗有效血浆水平。该装置可用于治疗骨关节炎，类风湿性关节炎和相关的炎性疾病。根据本发明，所述装置可用于使用与特定制剂组合的特定释放曲线递送Licofelone。

2. 发明申请

WO2006089494A9 OSMOTIC DEVICE CONTAINING AMANTADINE AND AN OSMOTIC SALT 审中-公开
标题翻译：含有金刚烷胺和渗透性盐的渗透装置
公开(公告)号：WO2006089494A9
公开(公告)日：2006-12-07
申请号：PCT/CR2005000005
申请日：2005-12-02
申请人： OSMOTICA COSTA RICA SA , MEYER GLENN A , FELEDER ETHEL C , RICCI MARCELO A , COPPARI MARCELO A , BEFUMO MARCELO E , FAOUR JOAQUINA , VERGEZ JUAN A
发明人： MEYER GLENN A , FELEDER ETHEL C , RICCI MARCELO A , COPPARI MARCELO A , BEFUMO MARCELO E , FAOUR JOAQUINA , VERGEZ JUAN A
IPC分类号： A61K31/13 , A61K9/20 , A61K9/28
CPC分类号： A61K31/13 , A61K9/0004 , A61K9/2009 , A61K9/2866
摘要： The invention relates to osmotic devices containing a unitary core which comprises an amantadine salt and an osmotic salt, in which the two salts have a common ion. The amantadine release speed is modified from a first order release profile to a zero order, pseudo zero order or sigmoidal release profile by increasing the quantity of osmotic salt in the core of the device. The osmotic device includes a semi-permeable membrane with a controlled porosity which can be adapted as required in order to co-operate with the osmotic salt in providing a pre-determined drug-release profile. The osmotic salt does not have to be covered and is mixed with the amantadine salt.
摘要翻译：本发明涉及含有单一核心的渗透装置，该核心包含金刚烷胺盐和渗透盐，其中两种盐具有共同的离子。通过增加装置核心中渗透盐的量，金刚烷胺释放速度从第一级释放曲线修改为零级，伪零级或S形释放曲线。渗透装置包括具有可控孔隙率的半透膜，其可根据需要进行调整以便与渗透盐配合以提供预定的药物释放曲线。渗透盐不必被覆盖并与金刚烷胺盐混合。

3. 发明申请

WO2004087116A3 DRUG COMBINATION FOR MOTOR DYSFUNCTION IN PARKINSON'S DISEASE 审中-公开
标题翻译：帕金森病中电机功能的药物组合
公开(公告)号：WO2004087116A3
公开(公告)日：2004-12-16
申请号：PCT/CR2004000003
申请日：2004-03-05
申请人： OSMOTICA COSTA RICA SA , VERGEZ JUAN A , LANIER ALAN B , FELEDER ETHEL C , MEYER GLENN A , RICCI MARCELO A , FAOUR JOAQUINA
发明人： VERGEZ JUAN A , LANIER ALAN B , FELEDER ETHEL C , MEYER GLENN A , RICCI MARCELO A , FAOUR JOAQUINA
IPC分类号： A61K31/00 , A61K45/06 , A61P25/16 , A61K31/13 , A61K31/137 , A61K31/343 , A61K31/506
CPC分类号： A61K45/06 , A61K31/00 , A61K31/137 , A61K31/343 , A61K31/452 , A61K2300/00
摘要： The invention relates to a method, and to the corresponding dosage form thereof, for the treatment of motor dysfunction associated with Parkinson's disease, using a drug treatment against Parkinson's disease, and/or with dementia associated with Parkinson's disease, for example, using levodopa therapy. The invention involves the combined administration of an antagonist of the NMDA receptor and an antidepressant, for example a combination of amantadine and citalopram or venlafaxine, or an antagonist of the NMDA receptor and an anxiolytic agent, for example amantadine and buspirone or trazodone, in order to improve unwanted tremors, akinesia, dyskinesia or bradykinesia associated with one or more different disorders or diseases. According to the invention, the drugs can be used in a single dosage form. One embodiment of the invention comprises a combined dosage form which contains each drug in controlled-release form. Another embodiment thereof comprises a combined dosage form which provides the controlled release of an antagonist of the NMDA receptor and the rapid release of a neuroactive agent following administration to the patient.
摘要翻译：本发明涉及一种方法及其相应的剂型，用于治疗与帕金森病相关的运动功能障碍，使用药物治疗帕金森病和/或与帕金森氏病相关的痴呆，例如使用左旋多巴治疗。本发明涉及NMDA受体和抗抑郁药的拮抗剂，例如金刚烷胺和西酞普兰或文拉法辛的组合，或NMDA受体的拮抗剂和抗焦虑剂（例如金刚烷胺和丁螺环酮或曲唑酮）的组合，按顺序改善与一种或多种不同疾病或疾病相关的不想要的震颤，运动障碍，运动障碍或运动迟缓。根据本发明，药物可以以单一剂型使用。本发明的一个实施方案包括含有受控释放形式的每种药物的组合剂型。其另一个实施方案包括组合剂型，其提供NMDA受体的拮抗剂的受控释放和在给予患者之后神经活性剂的快速释放。

4. 发明申请

WO2004056335A3 DELIVERY DEVICE CONTAINING VENLAFAXINE AND MEMANTINE AND USE METHOD THEREOF 审中-公开
标题翻译：包含文拉法辛和MEMANTINE的递送装置及其使用方法
公开(公告)号：WO2004056335A3
公开(公告)日：2004-11-25
申请号：PCT/CR0300004
申请日：2003-12-19
申请人： OSMOTICA COSTA RICA SA , VERGEZ JUAN A , FAOUR JOAQUINA , RICCI MARCELO A , PASTINI ANA C
发明人： VERGEZ JUAN A , FAOUR JOAQUINA , RICCI MARCELO A , PASTINI ANA C
IPC分类号： A61K9/00 , A61K9/24 , A61K31/13 , A61K31/135
CPC分类号： A61K45/06 , A61K9/0004 , A61K9/209
摘要： The present invention provides an osmotic device containing controlled release venlafaxine in the core in combination with an anti-Alzheimer's or an anti-Parkinson's drug in a rapid release external coat. Memantine is used as an anti-Alzheimer's drug or an anti-Parkinson's drug. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather than compression-coated onto the device. The device is useful for the treatment of depression in Alzheimer's and/or Parkinson's patients. The device and method can also be used to treat or ameliorate other symptoms associated with Alzheimer's disease, Parkinson's disease or any other neurological disorder. Other dosage forms that provide a controlled, sustained or extended release of venlafaxine in combination with a rapid or immediate release of memantine are useful in the invention.
摘要翻译：本发明提供了一种在核心中含有控释Venlafaxine的渗透装置，与快速释放外涂层中的抗阿尔茨海默氏病或抗帕金森病药物组合。美金刚用作抗阿尔茨海默氏病药物或抗帕金森病药物。本发明的特定实施例提供了具有预定释放曲线的渗透装置。渗透装置的一个实施例包括已经被喷涂而不是压缩涂覆到装置上的外部涂层。该装置可用于治疗阿尔茨海默病和/或帕金森病患者的抑郁症。该装置和方法还可以用于治疗或改善与阿尔茨海默病，帕金森病或任何其他神经疾病相关的其他症状。提供文拉法辛的受控，持续或延长释放以及美金刚的快速或即时释放的其它剂型可用于本发明。

5. 发明申请

WO2009000216A3 A RUPTURING CONTROLLED RELEASE DEVICE COMPRISING A SUBCOAT 审中-公开
标题翻译：一种包含SUBCOAT的破坏控制释放装置
公开(公告)号：WO2009000216A3
公开(公告)日：2009-07-16
申请号：PCT/CR2008000003
申请日：2008-06-26
申请人： OSMOTICA COSTA RICA SA , PASTINI ANA C , FAOUR JOAQUINA , VERGEZ JUAN A , RICCI MARCELO A , FISCHBEIN GUSTAVO A
发明人： PASTINI ANA C , FAOUR JOAQUINA , VERGEZ JUAN A , RICCI MARCELO A , FISCHBEIN GUSTAVO A
IPC分类号： A61K9/44
CPC分类号： A61K9/0004 , A61K31/195 , A61K31/403 , A61K31/4422 , A61K31/519 , A61K31/55 , A61K31/5513
摘要： The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane.
摘要翻译：本发明提供了一种简单和改进的破裂控制释放装置，其能够首先通过预先形成的通道提供包含在芯中的活性剂的受控释放，然后通过原位形成的第二通道进入标准化释放使用的环境配置方式。破裂控制释放装置包括芯，其包含至少一种药物和至少一种渗透性聚合物，包封芯的半透膜，并且在其中具有至少一个预制通道，其中半透膜在使用期间破裂以在半透膜中形成第二通道膜在与预成型通道隔开的位置处，以及在芯和半透膜之间的释放控制底涂层。

6. 发明申请

WO0151040B1 OSMOTIC DEVICE CONTAINING ALPRAZOLAM AND AN ANTIPSYCHOTIC AGENT 审中-公开
标题翻译：含有阿拉伯胶和抗惊厥剂的OSMOTIC装置
公开(公告)号：WO0151040B1
公开(公告)日：2002-03-07
申请号：PCT/US0100637
申请日：2001-01-09
申请人： OSMOTICA CORP , FAOUR JOAQUINA , VERGEZ JUAN A
发明人： FAOUR JOAQUINA , VERGEZ JUAN A
IPC分类号： A61K9/00 , A61K9/22 , A61K9/32 , A61K9/36 , A61K31/55 , A61K33/00 , A61K45/06 , A61K9/24
CPC分类号： A61K31/55 , A61K9/0004 , A61K33/00 , A61K45/06 , A61K31/505 , A61K31/00 , A61K2300/00
摘要： The present invention provides an osmotic device containing controlled release alprazolam in the core optionally in combination with an anti-psychotic agent, in a rapid release external coat. A wide range of anti-psychotic agents can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One preferred embodiment of the osmotic device includes an external coat that has been spray coated rather than compression coated onto the device. The device with spray coated external coat is smaller and easier to swallow than the similar device having a compression coated external coat. The device is useful for the treatment of depression, anxiety or psychosis related disorders.
摘要翻译：本发明提供了一种渗透装置，其包含在核心中的受控释放的阿普唑仑，任选地与抗精神病药组合，在快速释放外涂层中。在这种装置中可以使用各种抗精神病药。本发明的具体实施方案提供具有预定释放特征的渗透装置。渗透装置的一个优选实施例包括外涂层，其已被喷涂而不是压缩涂覆在该装置上。具有喷涂外涂层的装置比具有压缩外涂层的类似装置更小，更容易吞咽。该装置可用于治疗抑郁症，焦虑症或精神病相关疾病。

7. 发明申请

WO2006056145A3 OSMOTIC DEVICE CONTAINING A VENLAFAXINE SALT AND A SALT HAVING A COMMON ION 审中-公开
标题翻译：含有芬那芬盐和含有普通离子的盐的OSMOTIC装置
公开(公告)号：WO2006056145A3
公开(公告)日：2006-09-08
申请号：PCT/CR2005000001
申请日：2005-01-03
申请人： OSMOTICA CORP , FELEDER ETHEL C , MEYER GLENN A , RICCI MARCELO A , BEFUMO MARCELO F , FAOUR JOAQUINA , PASTINI ANA C
发明人： FELEDER ETHEL C , MEYER GLENN A , RICCI MARCELO A , BEFUMO MARCELO F , FAOUR JOAQUINA , PASTINI ANA C
IPC分类号： A61K9/32 , A61K9/00 , A61K9/24 , A61K31/13 , A61K31/137 , A61K31/277
CPC分类号： A61K9/0004 , A61K31/13 , A61K31/137 , A61K31/277
摘要： The invention relates to osmotic devices comprising a single core which contains a salt of a drug and an osmotic salt, wherein the drug salt and the osmotic salt have a common ion. According to the invention, the active drug release rate is reduced and the active drug release profile is modified from a first order release profile to a zero order, pseudo zero order or sigmoidal release profile by increasing the quantity of sodium chloride in the core of the device. In one embodiment of the invention, the sodium chloride is used to modify a controlled release profile to a controlled delayed release.
摘要翻译：本发明涉及包含含有药物和渗透盐的盐的单核的渗透装置，其中药物盐和渗透盐具有共同的离子。根据本发明，活性药物释放速率降低，并且将活性药物释放曲线从一级释放曲线修饰为零级，伪零级或S形释放曲线，通过增加核心中的氯化钠的量设备。在本发明的一个实施方案中，氯化钠用于将受控释放曲线改变为受控的延迟释放。

8. 发明申请

WO02058620A2 PHARMACEUTICAL COMPOSITIONS CONTAINING A COX-II INHIBITOR AND A MUSCLE RELAXANT 审中-公开
标题翻译：含有COX-II抑制剂和肌松弛剂的药物组合物
公开(公告)号：WO02058620A2
公开(公告)日：2002-08-01
申请号：PCT/CR0200001
申请日：2002-01-25
申请人： OSMOTICA COSTA RICA SA , FAOUR JOAQUINA , VERGEZ JUAN A
发明人： FAOUR JOAQUINA , VERGEZ JUAN A
IPC分类号： A61K45/06 , A61P21/02 , A61P25/04 , A61P29/00 , A61K
CPC分类号： A61K9/2054 , A61K9/0004 , A61K9/0014 , A61K9/0019 , A61K9/0095 , A61K9/02 , A61K9/2077 , A61K9/209 , A61K9/4866 , A61K9/5084 , A61K45/06
摘要： The invention relates to a pharmaceutical composition and a dosage form that combines a COX-II inhibitor and a muscle relaxant. The pharmaceutical composition is used to treat pain and disorders and symptoms associated with pain. The combination provides an improved therapeutic response compared to all other single drugs. The pharmaceutical composition can be administered in any dosage form.
摘要翻译：本发明涉及组合COX-II抑制剂和肌肉松弛剂的药物组合物和剂型。该药物组合物用于治疗与疼痛相关的疼痛和疾病和症状。与所有其他单一药物相比，该组合提供了改善的治疗反应。药物组合物可以以任何剂型施用。

9. 发明申请

WO2004087095A3 OSMOTIC CONTROLLED RELEASE DEVICE CONTAINING ZAFIRLUKAST AND AN H1-ANTAGONIST 审中-公开
标题翻译：含有ZAFIRLUKAST和H1-ANTAGONIST的OSMOTIC CONTROLLED RELEIS DEVICES
公开(公告)号：WO2004087095A3
公开(公告)日：2005-07-21
申请号：PCT/CR2004000004
申请日：2004-03-30
申请人： OSMOTICA COSTA RICA SA , VERGEZ JUAN A , FAOUR JOAQUINA , BEFUMO MARCELO F
发明人： VERGEZ JUAN A , FAOUR JOAQUINA , BEFUMO MARCELO F
IPC分类号： A61K9/00 , A61K31/404 , A61K31/445 , A61K31/506 , A61K9/22 , A61P11/06 , A61P29/00 , A61P37/08
CPC分类号： A61K9/0004
摘要： The invention relates to a controlled release device, e.g. an osmotic device, which releases zafirlukast in a controlled manner and which releases a H1 antagonist in a rapid and/or immediate manner. A wide range of antihistamine H1 antagonists, particularly loratadine, can be used in the inventive device. Specific embodiments of the invention comprise osmotic devices which release zafirlukast and a H1 antagonist in a controlled manner from the nucleus over an extended period of time. The aforementioned devices can be used for the treatment of allergic reactions, inflammation and asthma.
摘要翻译：本发明涉及一种控制释放装置，例如，渗透装置，其以受控的方式释放zafirlukast并且以快速和/或立即的方式释放H1拮抗剂。各种抗组胺药H1拮抗剂，特别是氯雷他定，可用于本发明的装置。本发明的具体实施方案包括渗透装置，所述渗透装置在长时间内以受控的方式从细胞核释放zafirlukast和H1拮抗剂。上述装置可用于治疗过敏反应，炎症和哮喘。

10. 发明申请

WO2004103349A3 BREAKABLE, CONTROLLED-RELEASE DEVICE COMPRISING A PREFORMED PASSAGE 审中-公开
标题翻译：包含预先通过的可断开的控制释放装置
公开(公告)号：WO2004103349A3
公开(公告)日：2005-03-31
申请号：PCT/CR2004000005
申请日：2004-05-21
申请人： OSMOTICA COSTA RICA SA , FAOUR JOAQUINA , VERGEZ JUAN A
发明人： FAOUR JOAQUINA , VERGEZ JUAN A
IPC分类号： A61K9/00 , A61K9/20 , A61K9/28
CPC分类号： A61K9/0004 , A61K9/209
摘要： The invention relates to a simple and improved osmotic device for the controlled release of an active agent from the core into the use environment. According to the invention, the active agent is first released through a preformed passage and, subsequently, through a second passage which is formed in situ. Optionally, the size of one or both of the passages increases during the use of the osmotic device. Moreover, the preformed passage and/or the second passage increases the release speed of the active agent and enables the release of larger particles containing the active agent and/or the release of active agents which are essentially insoluble in the use environment. Owing to the in situ formation of the second opening, the device can release a greater percentage of active agent than that which would be released without said second opening.
摘要翻译：本发明涉及用于将活性剂从核心控制释放到使用环境中的简单和改进的渗透装置。根据本发明，活性剂首先通过预制通道释放，随后通过原位形成的第二通道释放。任选地，在使用渗透装置期间，一个或两个通道的尺寸增加。此外，预制通道和/或第二通道增加了活性剂的释放速度，并且能够释放基本上不溶于使用环境的含有活性剂的较大颗粒和/或活性剂的释放。由于第二开口的原位形成，该装置可以比没有所述第二开口释放的活性剂释放更多的活性成分。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式